A Business Insider health reporter put one of the most talked-about cancer screening tools to the test, taking a $950 blood test that claims to detect signals for more than 50 cancers. The decision highlights a fast-growing market for multi-cancer early detection, where promise meets uncertainty and cost.
The reporter, Hilary Brueck, pursued the Galleri test from Grail and shared her experience with readers. The test is available in the United States by prescription. It is marketed for adults at elevated risk of cancer, typically those over 50, but it is not approved by the Food and Drug Administration as a routine screening tool.
“BI’s health correspondent Hilary Brueck took a $950 Grail’s Galleri blood test to detect more than 50 different cancers, then shared how she got on.”
What the Test Promises
Galleri screens a blood sample for fragments of DNA shed by cancer cells. The company says the test can flag a cancer “signal” and point to the likely tissue of origin, helping doctors decide next steps. It is not a diagnosis. Any positive result requires follow-up imaging or a biopsy.
Supporters see potential to catch cancers that lack standard screening, such as pancreatic, ovarian, and certain head and neck cancers. Clinicians also stress limits. The test may miss early cancers, and it can produce false alarms that lead to extra scans and anxiety.
How It Works and What It Can’t Do
Galleri analyzes chemical tags on DNA, often called methylation patterns. These tags differ between healthy and cancerous cells. A machine-learning model evaluates the patterns and estimates whether a cancer signal is present.
- It does not replace mammograms, colonoscopies, Pap tests, or low-dose CT scans.
- A negative result does not rule out cancer.
- A positive result needs confirmation by standard tests.
Researchers say performance varies by cancer type and stage. Sensitivity tends to be higher for advanced disease than for very early tumors, where early detection matters most.
Price, Access, and Clinical Advice
The test costs about $950 out of pocket in the U.S., and many insurers do not cover it. Patients need a clinician’s order, though telehealth services can provide one after screening for eligibility. For many, cost is a barrier. For others, the appeal is access to information that traditional screening may miss.
Professional groups advise caution. Because the test is a lab-developed test and not FDA approved for screening, doctors often recommend it only in the context of shared decision-making. That means reviewing risks, benefits, and possible outcomes before ordering it.
Evidence and Ongoing Trials
Early studies suggest the test can identify signals linked to several cancers and often point to where they started. Still, experts want clearer data on survival benefits and the balance between early finds and false positives.
Large trials are underway in the United States and the United Kingdom. Health systems are testing whether adding a multi-cancer blood test to standard screening leads to earlier diagnoses without too many unnecessary procedures. Results from these trials will guide policy, coverage, and clinical use.
Patient Experience and Next Steps After Testing
People who choose testing are often drawn by family history or worry about cancers that lack screening. A typical pathway after a positive result may include targeted imaging and, if needed, biopsy. After a negative result, doctors still recommend sticking to routine screenings.
Clinicians say preparation matters. Patients should understand how they will handle different outcomes, how follow-up would work, and what costs could add up if extra imaging is needed. Clear planning can reduce stress if results are unclear.
What It Means for Screening
Multi-cancer blood tests are arriving before the medical system has firm rules for them. Doctors, insurers, and regulators are watching for proof that they help people live longer and avoid harms from overtesting.
For now, the advice is steady. Discuss the test with a healthcare professional, keep up with proven screenings, and weigh the financial impact. New evidence could shift guidance, but careful use remains key.
Brueck’s decision to try the test shows the demand for earlier answers. It also shows why independent data, clear counseling, and fair coverage policies will matter as this field grows. Readers should watch for trial results in the next few years, which could determine whether tests like Galleri move from niche use to standard care.
